Table 1. Patient characteristics Patient... | American Society of Hematology

Table 1.

Patient characteristics

Patient characteristic	n or median	% or range
Total patients	67
PCNSL	58	68.6
SCNSL	9	13.4
Age (y)	69.6	27-85
Sex
Female	33	49.3
Male	34	50.7
ECOG PS ≥ 2	27	40.3
IELSG risk group
Low	7	10.4
Intermediate	41	61.2
High	19	28.4
Treatment
MATRix/MARTA	34	50.7
PRIMAIN	22	32.8
Other	11	16.4
HCT-ASCT	29	43.3
Consolidative WBRT	7	10.4
Relapse	20	29.9
Death	25	37.3
Follow-up survivors (mo)	17.5	4.1-54

Patient characteristic	n or median	% or range
Total patients	67
PCNSL	58	68.6
SCNSL	9	13.4
Age (y)	69.6	27-85
Sex
Female	33	49.3
Male	34	50.7
ECOG PS ≥ 2	27	40.3
IELSG risk group
Low	7	10.4
Intermediate	41	61.2
High	19	28.4
Treatment
MATRix/MARTA	34	50.7
PRIMAIN	22	32.8
Other	11	16.4
HCT-ASCT	29	43.3
Consolidative WBRT	7	10.4
Relapse	20	29.9
Death	25	37.3
Follow-up survivors (mo)	17.5	4.1-54

ECOG PS, Eastern Cooperative Oncology Group performance status; HCT-ASCT, high-dose chemotherapy followed by autologous stem cell transplantation; MARTA, methotrexate, cytarabine, and rituximab; MATRix, methotrexate, cytarabine, thiotepa, and rituximab; PRIMAIN, procarbazine, methotrexate, and rituximab; WBRT, whole-brain radiotherapy.

View Large

This Feature Is Available To Subscribers Only